Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 76

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 76
---
, Yissum communicated its
position that the final scientific report was delivered in September 2024 and that, accordingly, the option exercise period has already
lapsed. We dispute this position. We and Yissum are currently engaged in discussions to resolve this matter. There can be no assurance
that these discussions will result in an outcome that preserves our ability to exercise the option.

We intend to evaluate the results of a planned
large-animal safety study—now expected in the first half of 2026—before determining whether to proceed with an exclusive
license. Initiation of this study has been delayed pending receipt of what we consider to be the contractually required final scientific
report.

If we are unable to reach a resolution that
preserves our rights under the option agreement, or if we ultimately elect not to exercise the option based on the results of the large-animal
study, our development pipeline would exclude the Nano-Candesartan program. Such an outcome could materially affect our future development
plans and may require us to reassess the carrying value of intangible assets associated with the ARB program in accordance with ASC 350.
Any impairment charge or redirection of development resources could have a material adverse effect on our business, financial condition,
and results of operations.

<div align='center'>45

DESCRIPTION OF BUSINESS

Overview</div>

We are a pre-clinical stage biopharmaceutical
company focused on the development and eventual commercialization of innovative and proprietary nanoparticle-based therapies. We focus
on creating smarter, more targeted treatments that improve how medicines work in the body, with the goal of increasing effectiveness
while reducing side effects. We are developing unique lipid-based platforms for a variety of potential uses, including areas with high
unmet-needs such as antimicrobial resistance and solid tumors.

Our work is inspired by Prof. Barenholz, one
of the world’s leaders in this field and one of the original innovators behind liposomal drug delivery. His decades of research
have shaped some of today’s most important cancer treatments like Doxil ®. At Revium Rx, we’re taking this legacy further,
using our technology to develop next-generation therapies to help meet some of the most urgent medical needs.

Our programs are focused on infectious diseases,
including antibiotic-resistant infections, solid tumors and a novel approach to vaccination. We leverage advanced lipid-based delivery
systems with the aim of enhancing the safety, efficacy, and clinical utility of established therapeutics, while also exploring potential
new uses for existing